$8m in cash
$20m facility extended to 2026...
• R327 shown to significantly reduce SARS-CoV-2 in hamsters
R327 SARS-CoV-2 Study Update – Efficacious Activity in Animal Models
The Company was pleased to release the findings of its SARS-CoV-2 studies. Undertaken by
an independent, third-party contract research organisation (CRO), Netherlands-based CRO,
Viroclinics, saw its SARS-CoV-2 studies demonstrate significant efficacious activity of R327
against the SARS-CoV-2 virus in the throat of Syrian golden hamsters – the gold-standard in
COVID studies.
Throughout the ongoing studies, R327 was shown to significantly reduce SARS-CoV-2 levels
in a dose-dependent manner, in throat swab samples collected from animals. The study
provided proof-of-concept that intra-nasal treatment with R327 has the potential to reduce
SARS-CoV-2 levels during infection.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.005(0.97%) |
Mkt cap ! $120.5M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 52.0¢ | $4.485K | 8.497K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 14897 | 2 |
View Market Depth
| Last trade - 15.47pm 04/10/2024 (20 minute delay) ? |
| RCE (ASX) Chart |